ArticleTranslational lung cancer research2025
International cost-effectiveness analysis of nivolumab plus ipilimumab-based for metastatic non-small cell lung cancer with PD-L1 lower than 1.
Wolong Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.